Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in the 2021 Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 pm ET. The conference will feature a fireside chat with Maury Raycroft. A live audio webcast will be available on IDEAYA's website, with a replay accessible for 30 days following the event. IDEAYA focuses on synthetic lethality and precision medicine for oncology, integrating biomarker identification with drug discovery to enhance targeted therapeutics.

IDEAYA Biosciences (Nasdaq:IDYA) reported a business update and financial results for Q1 2021, highlighting development in its clinical trials, especially for IDE397, a MAT2A inhibitor targeting MTAP deletion tumors. The company announced a net loss of $9.0 million compared to $5.1 million in the previous quarter, with cash reserves amounting to $310.4 million. Collaboration revenue decreased to $7.2 million from $10.6 million. IDEAYA also expects to achieve multiple preclinical and clinical milestones across its targeted synthetic lethality programs in 2021 and beyond.

IDEAYA Biosciences (NASDAQ: IDYA) announced the dose expansion of its Phase 1/2 study on the darovasertib and crizotinib combination therapy for metastatic uveal melanoma (MUM). Encouraging early results indicate tumor reduction in two evaluable patients, including a notable 54% reduction in one patient. Despite drug-related adverse events such as syncope and hypotension, the combination therapy shows promise. Further patient enrollment continues as IDEAYA aims to explore additional doses, building on preliminary data and preclinical findings presented at AACR 2021.

IDEAYA Biosciences (NASDAQ: IDYA) announced its participation in the upcoming 2021 JP Morgan Conference Call Series. The fireside chat with analyst Anupam Rama will take place on May 10, 2021, at 11:00 am ET. A live audio webcast will be accessible on the IDEAYA website's Investor Calendar section, with a replay available for 30 days after the event. IDEAYA focuses on precision medicine oncology, particularly through synthetic lethality, aiming to develop targeted therapeutics based on molecular diagnostics.

IDEAYA Biosciences (NASDAQ: IDYA) announced its inaugural Synthetic Lethality Investor Day scheduled for April 20, 2021, from 1:00 pm to 3:00 pm ET. The virtual event will feature presentations from key opinion leaders and scientists from IDEAYA and GlaxoSmithKline (GSK), focusing on synthetic lethality in precision medicine. Topics include IDE397 targeting MAT2A in MTAP-deleted tumors and innovative cancer treatment strategies. Registration details are available on IDEAYA's website.

IDEAYA Biosciences (NASDAQ: IDYA) announced promising results from its ongoing Phase 1/2 trial of darovasertib (IDE196) for treating solid tumors, including Metastatic Uveal Melanoma (MUM). Key findings include a 57% one-year overall survival rate in heavily pre-treated MUM patients, compared to a historical rate of 37%. Additionally, 61% of MUM patients showed tumor reduction. The combination therapy with binimetinib also yielded early results, with 22% of MUM patients showing partial responses. The company continues its clinical development focus and will host an investor webcast for further insights.

IDEAYA Biosciences (NASDAQ: IDYA) announced an upcoming webcast on April 16, 2021, to discuss clinical data from its Phase 1/2 trial evaluating darovasertib (IDE196) as monotherapy and in combination with binimetinib for treating metastatic uveal melanoma. The company will host an Investor Day featuring leading clinical investigators. Additionally, the International Nonproprietary Name for IDE196 has been confirmed as darovasertib by WHO. The press release cautions investors about risks in drug development and the potential impacts of COVID-19 on business operations.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) has announced the dosing of the first patient in its Phase 1 clinical trial of IDE397, a methionine adenosyltransferase 2a (MAT2A) inhibitor, targeting patients with methylthioadenosine phosphorylase (MTAP) deletion, which occurs in about 15% of solid tumors. IDE397 has shown promising anti-tumor activity across various solid tumor types, including non-small cell lung cancer and gastric cancer. The trial's progress involves activating multiple clinical sites in the U.S. and using Next Generation Sequencing for patient identification.

IDEAYA Biosciences (Nasdaq:IDYA) provided a business update and reported financial results for Q4 2020. The company advanced IDE397 into Phase 1 for treating solid tumors with MTAP deletions, representing about 15% of all solid tumors. IDEAYA's pipeline includes significant progress in IDE196 and plans for Development Candidate nominations for PARG and Pol Theta programs in 2021. Financially, IDEAYA reported a net loss of $5.1 million for Q4 2020, improved from $10.8 million in Q4 2019, and held $283.6 million in cash and equivalents as of December 31, 2020.